Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Bezborodova Oa"'
Autor:
Maxim M. Shmarov, I. L. Tutykhina, Raisa I. Yakubovskaya, V. I. Chissov, D. Yu. Logunov, B. S. Naroditskii, Alexander L. Gintsburg, Bezborodova Oa, E. R. Nemtsova
Publikováno v:
Molecular Genetics, Microbiology and Virology. 25:77-83
A recombinant pseudoadenovirus nanostructure (RPAN) based on human adenovirus of the 5th serotype that carries the human Lf gene was constructed to develop an effective system of human lactoferrin (Lf) production. It was shown using the model of toxi
Autor:
E. R. Nemtsova, A. L. Ginzburg, I. L. Tutykhina, Raisa I. Yakubovskaya, D. Yu. Logunov, Maxim M. Shmarov, L. V. Verkhovskaya, B. S. Naroditskii, Bezborodova Oa
Publikováno v:
Molecular Genetics, Microbiology and Virology. 24:32-36
The method of homologous recombination in E. coli cells was used to obtain a pseudoadenovirus nanostructure Ad5-lf that ensures the effective expression of the lactoferrin (Lf) gene in a permissive cell system with the high production of recombinant
Autor:
E. R. Nemtsova, Galina L. Neugodova, Denis Y. Logunov, Maxim M. Shmarov, Boris S. Naroditsky, Bezborodova Oa, Raisa I. Yakubovskaya, Alexander L. Gintsburg, I. L. Tutykhina
Publikováno v:
Protein expression and purification. 65(1)
The human iron-binding protein lactoferrin (hLf) has been implicated in a number of important physiological pathways, including those regulating immune function and tumor growth. In an effort to develop an efficient system for production of recombina
Autor:
I. V. Alekseenko, E. P. Kopantzev, Galina S. Monastyrskaya, E. V. Snezhkov, Igor P. Chernov, E.D. Sverdlov, Alexey V. Ulasov, Andrey A. Rosenkranz, V. K. Potapov, Bezborodova Oa, Anna D. Plyutinskaya, Alexander S. Sobolev, A. V. Sass, Raisa I. Yakubovskaya, Yuri V. Khramtsov, E. R. Nemtsova, Tatyana V. Vinogradova, V. V. Pleshkan
Publikováno v:
Journal of Translational Medicine
Background Gene-directed enzyme prodrug therapy (GDEPT) represents a technology to improve drug selectivity for cancer cells. It consists of delivery into tumor cells of a suicide gene responsible for in situ conversion of a prodrug into cytotoxic me
Production of recombinant human interferon beta and lactoferrin in chicken cells in vitro and in ovo
Autor:
M M Shmarov, B.S. Naroditsky, D. Yu. Logunov, M.V. Mezenceva, Iakubovskaia Ri, E. A. Cherentaeva, Bezborodova Oa, I. L. Tutykhina, E. R. Nemtsova, A L Gintsburg
Publikováno v:
New Biotechnology. 25:S7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Bezborodova OA; Moscow Hertzen Research Institute of Oncology- branch of National Medical Radiology Research Center, Ministry of Health of the Russian Federation, 2(nd) Botkinsky Passage 3, Moscow 125284, Russia. Electronic address: olgabezborodova@yandex.ru., Pankratov AA; Moscow Hertzen Research Institute of Oncology- branch of National Medical Radiology Research Center, Ministry of Health of the Russian Federation, 2(nd) Botkinsky Passage 3, Moscow 125284, Russia., Kogan BY; Organic Intermediates and Dyes Institute, B. Sadovaya 1/4, Moscow 123995, Russia,. Electronic address: bkogan@mail.mipt.ru., Nemtsova ER; Moscow Hertzen Research Institute of Oncology- branch of National Medical Radiology Research Center, Ministry of Health of the Russian Federation, 2(nd) Botkinsky Passage 3, Moscow 125284, Russia. Electronic address: nemtz@yandex.ru., Venediktova JB; Moscow Hertzen Research Institute of Oncology- branch of National Medical Radiology Research Center, Ministry of Health of the Russian Federation, 2(nd) Botkinsky Passage 3, Moscow 125284, Russia. Electronic address: uluaz@yandex.ru., Karmakova TA; Moscow Hertzen Research Institute of Oncology- branch of National Medical Radiology Research Center, Ministry of Health of the Russian Federation, 2(nd) Botkinsky Passage 3, Moscow 125284, Russia. Electronic address: kalmar123@yandex.ru., Butenin AV; Organic Intermediates and Dyes Institute, B. Sadovaya 1/4, Moscow 123995, Russia,. Electronic address: abutenin@yandex.ru., Feizulova RK; Organic Intermediates and Dyes Institute, B. Sadovaya 1/4, Moscow 123995, Russia,. Electronic address: rfeizulova@yandex.ru., Khokhlova VA; Moscow Hertzen Research Institute of Oncology- branch of National Medical Radiology Research Center, Ministry of Health of the Russian Federation, 2(nd) Botkinsky Passage 3, Moscow 125284, Russia. Electronic address: nostocus@yandex.ru., Obraztsova EA; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya 16/10, Moscow 117997, Russia. Electronic address: aobraztsova@yandex.ru., Kaprin AD; Moscow Hertzen Research Institute of Oncology- branch of National Medical Radiology Research Center, Ministry of Health of the Russian Federation, 2(nd) Botkinsky Passage 3, Moscow 125284, Russia. Electronic address: kaprin@mail.ru.
Publikováno v:
Nanomedicine : nanotechnology, biology, and medicine [Nanomedicine] 2024 Jun 28; Vol. 61, pp. 102768. Date of Electronic Publication: 2024 Jun 28.
Autor:
Rakitina OA; Group of Gene Immuno-Oncotherapy, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia., Kuzmich AI; Group of Gene Immuno-Oncotherapy, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia., Bezborodova OA; Group of Gene Immuno-Oncotherapy, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia., Kondratieva SA; Group of Gene Immuno-Oncotherapy, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia., Pleshkan VV; Group of Gene Immuno-Oncotherapy, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia., Zinovyeva MV; Group of Gene Immuno-Oncotherapy, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia., Didych DA; Group of Gene Immuno-Oncotherapy, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia., Sass AV; Group of Gene Immuno-Oncotherapy, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia., Snezhkov EV; Laboratory of Human Gene Structure and Functions, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia., Kostina MB; Group of Gene Immuno-Oncotherapy, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia., Koksharov MO; Group of Gene Immuno-Oncotherapy, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia.; Stagen LLC, Moscow, Russia., Alekseenko IV; Group of Gene Immuno-Oncotherapy, Department of Genomics and Postgenomic Technologies, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia.; Stagen LLC, Moscow, Russia.
Publikováno v:
Frontiers in immunology [Front Immunol] 2024 Jun 26; Vol. 15, pp. 1410564. Date of Electronic Publication: 2024 Jun 26 (Print Publication: 2024).
Autor:
Shestovskaya MV; Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Pogodinskaya st. 10/1, Moscow 119435, Russia. Electronic address: MShestovskaya@cspfmba.ru., Luss AL; Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Pogodinskaya st. 10/1, Moscow 119435, Russia., Bezborodova OA; P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, 2nd Botkinskiy p. 3, Moscow 125284, Russia., Kulikov PP; Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Pogodinskaya st. 10/1, Moscow 119435, Russia., Antufrieva DA; Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Pogodinskaya st. 10/1, Moscow 119435, Russia., Plotnikova EA; P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, 2nd Botkinskiy p. 3, Moscow 125284, Russia., Makarov VV; Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Pogodinskaya st. 10/1, Moscow 119435, Russia., Yudin VS; Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Pogodinskaya st. 10/1, Moscow 119435, Russia., Pankratov AA; P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, 2nd Botkinskiy p. 3, Moscow 125284, Russia., Keskinov AA; Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Pogodinskaya st. 10/1, Moscow 119435, Russia.
Publikováno v:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Jun; Vol. 175, pp. 116668. Date of Electronic Publication: 2024 May 02.
Autor:
Shestovskaya MV; Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Schukinskaya st. 5/1, Moscow 119435, Russia., Luss AL; Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Schukinskaya st. 5/1, Moscow 119435, Russia.; The Department of Technology of Chemical, Pharmaceutical and Cosmetic Products Mendeleev of University of Chemical Technology of Russia, Miusskaya sq. 9, Moscow 125047, Russia., Bezborodova OA; P. Hertsen Moscow Oncology Research Institute of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, 2nd Botkinskiy p. 3, Moscow 125284, Russia., Makarov VV; Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Schukinskaya st. 5/1, Moscow 119435, Russia., Keskinov AA; Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Schukinskaya st. 5/1, Moscow 119435, Russia.
Publikováno v:
Pharmaceutics [Pharmaceutics] 2023 Sep 30; Vol. 15 (10). Date of Electronic Publication: 2023 Sep 30.